Medical devices to treat or inhibit restenosis
First Claim
1. An implantable medical device for the treatment or inhibition of restenosis coated with a KSP inhibitor selected from the group consisting of CK-0238273 as depicted in Formula 1, and pharmaceutically acceptable derivatives thereof.
1 Assignment
0 Petitions
Accused Products
Abstract
Implantable medical devices having anti-restenotic coatings are disclosed. Specifically, implantable medical devices having coatings of certain antiproliferative agents, particularly a certain KSP inhibitor, are disclosed. The anti-restenotic KSP inhibitor is CK-0238273, and pharmaceutically acceptable derivatives thereof. The anti-restenotic medical devices include stents, catheters, micro-particles, probes and vascular grafts. Intravascular stents are preferred medical devices. The medical devices can be coated using any method known in the art including compounding the KSP inhibitor with a biocompatible polymer prior to applying the coating. Moreover, medical devices composed entirely of biocompatible polymer-KSP inhibitor blends are disclosed. Additionally, medical devices having a coating comprising at least one KSP inhibitor in combination with at least one additional therapeutic agent are also disclosed. Furthermore, related methods of using and making the anti-restenotic implantable devices are also disclosed.
143 Citations
14 Claims
- 1. An implantable medical device for the treatment or inhibition of restenosis coated with a KSP inhibitor selected from the group consisting of CK-0238273 as depicted in Formula 1, and pharmaceutically acceptable derivatives thereof.
- 5. An intravascular stent for site-specific, controlled-release delivery of a medicament for the treatment or inhibition of restenosis, said stent having a coating comprising a biocompatible polymer and a KSP inhibitor selected from the group consisting of CK-0238273 as depicted in Formula 1, and pharmaceutically acceptable derivatives thereof.
-
9. A method of treating or inhibiting restenosis comprising:
-
providing an intravascular stent having a coating comprising a KSP inhibitor selected from the group consisting of CK-0238273 as depicted in Formula 1, and pharmaceutically acceptable derivatives thereof; and
implanting said intravascular stent into a blood vessel lumen at risk for restenosis wherein said KSP inhibitor is released into tissue adjacent said blood vessel lumen in a controlled release manner. - View Dependent Claims (10)
-
-
11. A method for producing a medical device comprising:
-
providing medical device to be coated;
compounding CK-0238273 as depicted in Formula 1, or a pharmaceutically acceptable derivative thereof with a carrier compound; and
coating said medical device with said CK-0238273 or pharmaceutically acceptable derivative thereof compounded with said carrier compound. - View Dependent Claims (12, 13, 14)
-
Specification